HCPLive | Medical News and Conference Coverage for Health Care Professionals

The Women's Cancer Blog

Lymph Nodes and Breast Cancer? Is Less as Good?

Monday, February 28th, 2011

How important is a completion node dissection for women with a positive sentinel node biopsy in breast cancer?

PARP Inhibitors in Triple-negative Breast Cancer

Friday, February 25th, 2011

PARP inhibitors are of significant interest to those who treat breast and gynecologic cancers, as they have shown such promise in BRCA-mutation related cancers.

Is There a Future for PARP Inhibitors in Ovarian Cancer?

Monday, November 29th, 2010

PARP inhibitors are promising agents, particularly for cancers associated with BRCA gene mutations.

Does IVF Cause an Increased Risk of Cancer?

Wednesday, November 24th, 2010

A recent study addressed the cancer risks associated with in vitro fertilization (IVF).

Addressing Chemotherapy Induced Ovarian Failure in Patients With Breast Cancer

Friday, October 29th, 2010

One of the biggest quality of life issues affecting young women treated with chemotherapy for breast cancer is chemotherapy induced ovarian failure.

Treating Breast Cancer in Pregnancy Affords a Survival Advantage

Monday, October 25th, 2010

An abstract presented at 2010 Breast Cancer Symposium analyzed pregnant women with breast cancer.

Save The Date: The National Consortium of Breast Centers 2011 Meeting

Monday, September 27th, 2010

The National Consortium of Breast Centers next annual meeting is March 12-16, 2011. The meeting will feature a special opening plenary session.

Preserving Future Fertility: The Artificial Ovary

Friday, September 24th, 2010

Researchers at Brown University have built an artificial human ovary that can grow oocytes into mature human eggs in the laboratory.

What Do I Do Now?

Monday, September 20th, 2010

The treatment of locally advanced breast cancer that does not completely resolve following neoadjuvant chemotherapy is unclear.

Cost-Utility Analysis and Trastuzumab

Tuesday, August 31st, 2010

For patients with HER-2 positive metastatic breast cancer, chemotherapy with trastuzumab is the gold standard.

Don S. Dizon, MD, FACP

Blog Info

This blog will focus on new developments in these fields as reported from national meetings and publications to bring a non-physician perspective to the revolution ongoing in the diagnosis and management of women's oncology.

Author Bio

Dr. Dizon is the Director of Medical Oncology, Integrative Care, and Co-Director of the Center for Sexuality, Intimacy and Fertility at the Program in Women's Oncology at Women and Infants Hospital of Rhode Island. His practice is tailored to breast and gynecologic malignancies and he remains active in clinical research through the Gynecologic Oncology Group and Brown University Oncology Group. He is an Associate Professor of Obstetrics-Gynecology and Associate Professor of Medicine at Alpert Medical School of Brown University.